Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Imipramine

Plain-language summaryIntrigue 60 / 100

Imipramine is historically the most important antidepressant ever made: Roland Kuhn at Geigy noticed in 1958 that this antihistamine candidate unexpectedly lifted depressed patients’ moods, which kicked off the entire monoamine theory of depression and the modern era of psychiatric pharmacology. Mechanically it blocks the serotonin and norepinephrine pumps in roughly balanced fashion, while also blocking acetylcholine, histamine, and alpha-1 adrenergic receptors as side activities. Today it sees mostly historical and academic use, plus a niche role in nocturnal enuresis (bedwetting) in children. The cardiac sodium channel block makes overdose lethal, which is one reason SSRIs displaced it once they became available. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

34/100

The 1958 prototype TCA, historically foundational but superseded by cleaner tools at every research axis

Look, imipramine is the Adam compound of synthetic antidepressant pharmacology. Roland Kuhn’s 1958 Geigy observation that the dibenzazepine scaffold relieved depressive symptoms launched the monoamine hypothesis and gave the field its first real conceptual framework. That history is genuinely significant. What the rubric asks is something different: how compelling is THIS compound as an active bench target right now, and the honest answer is, not very.

The mechanism is completely characterized and has been for decades. SERT inhibition at roughly 1 nM Ki, NET inhibition at ~21 nM, plus a well-mapped off-target profile covering muscarinic M1, H1, alpha-1 adrenergic, and voltage-gated sodium channels. The off-target hits that were once clinical liabilities remain liabilities now, not research opportunities. Nobody’s building a new program around imipramine’s anticholinergic activity when you can isolate those mechanisms cleanly elsewhere with better-characterized probes.

The differentiation problem is the sharpest drag here. Imipramine is superseded by its own active metabolite: desipramine is a cleaner, more NET-selective secondary amine that most investigators reach for when they want a TCA probe for norepinephrine transporter work specifically. For SERT-selective work, the entire SSRI class exists. For balanced dual inhibition, duloxetine and venlafaxine offer better tolerability and considerably cleaner pharmacology. Imipramine loses on almost every axis to something developed after it. Thats not a knock on historical significance, its just the reality of a 67-year-old compound in a mature drug class where every successive generation improved on the scaffold.

Where it retains real value is narrow: positive control in pharmacology assays requiring the canonical first-generation TCA, CYP2D6 and CYP2C19 probe substrate work, and research programs specifically examining the TCA class for historical comparison or mechanistic archaeology. The evidence base is genuinely solid, sixty-plus years of replicated clinical data, FDA approval across MDD, enuresis, and panic disorder, robust translational signal. But that signal describes clinical applications modern practice has largely moved past, and solid old evidence doesn’t make a compound interesting.

We think the honest landing for imipramine is important reference compound with narrow active bench utility. The evidence quality and translational signal keep the score from falling further, but the novelty floor and severely penalized differentiation pull it squarely into the same tier as piracetam: historically central to the field, currently deprioritized by most investigators chasing something with more headroom.

Novelty

15

Mechanism promise

22

In-category differentiation

15

Evidence quality

65

Translational signal

65

Research bench value

45

Rationale Imipramine scores hard at the bottom of novelty and differentiation because it’s a 1958 compound outcompeted by its own active metabolite (desipramine) and the entire SSRI/SNRI class; evidence quality and translational signal are genuinely solid but for indications modern practice has largely moved past, producing an overall that sits in the same tier as piracetam.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant (tertiary amine; first synthetic antidepressant)

The first synthetic antidepressant; the parent compound of the TCA class and the historical reference for monoamine theory of depression.

Abstract

Imipramine (3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine; CAS 50-49-7; molecular formula C19H24N2; molecular weight 280.41) is a dibenzazepine tertiary amine TCA developed at Geigy by Roland Kuhn in 1958, the first synthetic compound demonstrated to relieve depressive symptoms in clinical trial. The historical observation underpinned the catecholamine hypothesis of depression and launched modern psychopharmacology. SERT and NET affinities are balanced (SERT Ki approximately 1 nM, NET Ki approximately 21 nM); the active metabolite desipramine is a NET-preferring secondary amine. Off-target activity parallels amitriptyline: muscarinic, H1, alpha-1, and sodium channel block. Plasma half-life is 11 to 25 hours; metabolism is via CYP2D6 and CYP2C19. Approved for major depressive disorder; clinical use today focuses on enuresis (bedwetting) in children (low-dose for anticholinergic and alpha-1 effects on bladder) and panic disorder. The TCA cardiotoxicity profile is the principal limitation. Used as the historical reference TCA and the prototype monoamine reuptake inhibitor in pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-218Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Desipramine

Plain-language summaryIntrigue 53 / 100

Desipramine (Norpramin) is the active leftover of imipramine, FDA-approved in 1964, and the most norepinephrine-selective tricyclic antidepressant ever brought to market. The shift in selectivity comes from removing one methyl group from imipramine. The strongly noradrenergic profile makes it one of the more activating tricyclics and useful in attention deficit research, although it never gained an ADHD label. Compared to its parent it has lower anticholinergic and antihistamine burden, so it is somewhat better tolerated, but it shares the cardiac conduction problems of the whole tricyclic class and overdose is dangerous. Used in treatment-resistant depression and some neuropathic pain protocols. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

44/100

The canonical NET-selective TCA; useful as a noradrenergic reference probe but essentially exhausted as a research frontier

Look, desipramine is about as established as it gets in the TCA class. FDA-approved in 1964, it’s been the reference standard for NET-selective tricyclic pharmacology for sixty years. That dual status, canonical probe on one hand and dated workhorse on the other, is exactly what drives the score here.

The NET selectivity is real and it matters. A Ki of roughly 0.83 nM at NET versus 17 nM at SERT gives you a selectivity ratio around 20-fold, which is genuinely useful if you’re trying to dissect noradrenergic from serotonergic contributions in a mixed-reuptake experiment. Compared to imipramine, the parent compound, desipramine sheds meaningful muscarinic (M1 Ki around 200 nM) and H1 load while keeping the NET hit clean. For any investigator running catecholamine reuptake assays, building pharmacological controls, or studying NE dynamics in pain or ADHD-relevant circuits, its position as the canonical NET-selective TCA is hard to displace within that specific context. Thats the bench case for having it in the library.

But thats also where the excitement ends. The mechanism, NET reuptake inhibition, has been understood for sixty years. The binding kinetics are fully characterized, the downstream noradrenergic effects are mapped, and the CYP2D6/CYP2E1 metabolism profile is textbook. What we dont like is that atomoxetine and reboxetine both exist now, offering higher NET selectivity without the TCA off-target load. For pure noradrenergic questions, those compounds have largely superseded desipramine except in historical comparisons or when the TCA scaffold itself is under study.

The evidence base is enormous. Multiple phase 3 trials, decades of replicated clinical data, strong meta-analytic signal for MDD. Translational signal is unambiguous in the sense that it works in people and that fact is exhaustively documented. But from a research novelty standpoint, a large evidence base on a 60-year-old compound means less remaining question to answer. There’s no frontier in the depression indication, the neuropathic pain angle is mature, and the ADHD off-label use lives in the shadow of better-characterized and more selective tools.

We think desipramine earns its place in the library as a reference compound and nothing more. Investigators comparing noradrenergic agents, running assay controls, or building pharmacological models of NE reuptake will want it on the shelf. For anything asking a genuinely new question about human biology, the novelty and mechanism scores drag the overall to where it belongs: a well-characterized, historically important, presently limited research tool.

Novelty

18

Mechanism promise

28

In-category differentiation

40

Evidence quality

72

Translational signal

68

Research bench value

60

Rationale Desipramine scores well on evidence and translational signal because its pharmacology is thoroughly characterized over six decades, but those same qualities crush its novelty and mechanism scores. Its bench value is real but narrow: it functions as a reference standard for NET-selective TCA comparisons, not as a frontier compound worth pursuing for new biology.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant (secondary amine)

The N-desmethyl active metabolite of imipramine; the most NET-selective TCA in clinical use.

Abstract

Desipramine (3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine; CAS 50-47-5; molecular formula C18H22N2; molecular weight 266.38) is the N-desmethyl active metabolite of imipramine, approved by the FDA in 1964 under the trade name Norpramin. The compound is the most NET-selective TCA in clinical use (NET Ki approximately 0.83 nM, SERT Ki approximately 17 nM, ratio approximately 20). Off-target activity is reduced compared to imipramine: muscarinic (M1 Ki approximately 200 nM), H1 (Ki approximately 60 nM), and alpha-1 (Ki approximately 100 nM) antagonism are all weaker than the parent compound, producing a cleaner profile though still TCA-like. Plasma half-life is 15 to 24 hours; metabolism is via CYP2D6 and CYP2E1. Approved for major depressive disorder; used at higher doses (150 to 300 mg) for moderate-severe depression, at lower doses for ADHD (off-label) and neuropathic pain. Sodium channel block and consequent cardiotoxicity in overdose remain limitations. Used as the canonical NET-selective TCA in mechanism studies and as a reference compound for noradrenergic pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-219Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Thymopentin

Plain-language summaryIntrigue 50 / 100

Thymopentin is a 5-amino-acid synthetic peptide representing the active region of thymopoietin. Used historically for psoriasis and immune modulation. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

A mature thymic pentapeptide with real approvals but overshadowed by thymosin alpha-1 across every meaningful axis

Look, thymopentin is a legitimate compound. Arg-Lys-Asp-Val-Tyr, five residues that happen to capture most of thymopoietin’s functional activity in a peptide you can synthesize cleanly and administer subcutaneously. It’s approved in Italy under the Timunox brand, approved in China and several other Asian markets for primary immunodeficiency and hepatitis B support, and has been used in clinical practice for decades. That’s not nothing. The compound is real, the mechanism is real, the human data is real.

The problem is context. When you look at where the thymic peptide space actually sits today, thymopentin is the compound you consider before you remember that thymosin alpha-1 exists. Zadaxin has broader regulatory approval, a more extensive multi-center trial base, better-characterized cytokine kinetics, and a cleaner reputation in the literature. If youre building a research program around thymic biology and T-cell maturation, thymopentin isnt where you start. It’s where you end up if thymosin alpha-1 is unavailable or if you have a specific reason to work with the thymopoietin fragment specifically.

The mechanism is genuinely interesting in principle: the compound appears to promote thymocyte maturation, modulates the CD4/CD8 ratio, and has documented NK cell effects. We don’t dismiss that. But the biology here is well-trodden 1980s immunopharmacology. The trials supporting its approvals predate modern RCT standards. Most of the published literature comes from the era when open-label studies in Eastern European and Asian centers were the standard of evidence, and replication across independent Western lab groups is thin.

What we find most limiting is the differentiation story. The thymic peptide category has a clear hierarchy, and thymopentin isn’t at the top. Thymosin alpha-1 outperforms it on evidence density, indication breadth, and regulatory reach. Thymosin beta-4 fragments occupy a different but increasingly interesting niche. Thymopentin sits in the middle: approved, real, known, but not best-in-class on any axis that matters for a serious research prioritization decision in 2025.

There is some bench value here. If you’re specifically investigating the thymopoietin receptor axis, or studying the minimal active fragment hypothesis in thymic hormone biology, thymopentin is the obvious probe. The five-residue sequence is well-defined and commercially available from reputable peptide vendors, which matters for reproducibility. We think this is where its research merit is most defensible: as a structural probe for a well-mapped biology, not as a frontier target. Honest assessment puts it in the established-mature bucket, useful but not urgent, and a distant second to the compounds that have pushed this field forward more recently.

Novelty

32

Mechanism promise

38

In-category differentiation

25

Evidence quality

48

Translational signal

52

Research bench value

40

Rationale Thymopentin has genuine regulatory standing in Italy and several Asian markets, which pushes evidence and translational scores above peptides stuck in preclinical purgatory, but it sits squarely behind thymosin alpha-1 on differentiation and behind newer immunomodulatory targets on novelty. The thymic peptide biology is real and the pentapeptide design is elegant, but this is 1980s-era pharmacology competing in a field that has moved on.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic pentapeptide of thymopoietin

A synthetic pentapeptide fragment (residues 32-36) of thymopoietin marketed in Europe and Asia for immunomodulation in chronic infections and autoimmune disease.

Abstract

Thymopentin (Timunox, TP-5; Arg-Lys-Asp-Val-Tyr; CAS 69558-55-0; molecular weight 679.78) is a synthetic pentapeptide corresponding to residues 32-36 of thymopoietin, a thymic hormone. The fragment retains the immunomodulatory activity of full-length thymopoietin. The compound is approved in Italy and several Asian countries for primary immunodeficiency, hepatitis B, atopic dermatitis adjunct, and autoimmune disease support. Mechanism includes T-cell maturation, NK cell modulation, and cytokine balance effects. Administered subcutaneously. Doses are 50 mg three times weekly in clinical use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-130Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Thymogen

Plain-language summaryIntrigue 45 / 100

Thymogen is a synthetic dipeptide (Glu-Trp) immunomodulator developed in Russia, derived from research on thymic hormones. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

37/100

Russian-approved thymic dipeptide with real but geographically isolated evidence and conventional immunomodulatory mechanism

Thymogen is the synthetic Glu-Trp dipeptide, pulled from bovine thymus extract by the fractionation work that produced the broader thymalin literature. It’s a legitimately interesting research object in a narrow sense: two amino acids, modest immunomodulatory activity, and a regulatory approval history that puts it above the purely speculative tier. But we have to be honest about what we’re dealing with here.

The mechanism story is straightforward and not especially exciting. Thymic peptides generally modulate T-cell maturation and cytokine output, and Thymogen does this at the dipeptide level. Thats useful to know, but the actual pharmacology is conventional thymic biology, not a novel axis. Compare it to thymosin alpha-1, which has a much richer literature, phase 2/3 trial experience in HIV and hepatitis, and real credibility in the immunostimulant space. Against that competition, Thymogen is clearly secondary.

The evidence situation is the main drag. The literature is almost entirely Russian-language, produced within a small set of institutes associated with the Khavinson/bioregulator tradition. Regulatory approval in Russia and several former Soviet states means there’s real clinical use, but the methodology behind those approvals is opaque by Western standards. There’s essentially no independent multi-lab replication, no phase 2/3 data by EMA or FDA standards, and no published systematic reviews we can assess with confidence.

What we like: the synthetic dipeptide approach is clean. If someone wants to study minimal thymic signaling molecules as probes for T-cell maturation pathways, Thymogen is small, well-defined, and accessible. That’s genuinely more useful than starting with a crude thymus extract. And the intranasal route is interesting from a delivery standpoint if you’re studying mucosal immune signaling in rodent models.

What we don’t like: the mechanism doesn’t differentiate it from better-studied alternatives in the thymic peptide space. Thymosin alpha-1 exists. Thymopentin exists. The Glu-Trp story hasn’t generated the kind of mechanism-deep papers that would justify prioritizing this over those options for a serious research program. The approved-in-Russia status is worth noting but doesn’t substitute for replication outside that regulatory tradition.

For investigators specifically building out a thymic peptide panel or studying minimal bioactive dipeptides as a structural class, Thymogen has real bench value. For most Western research contexts, the evidence base doesn’t justify leading with it over better-characterized alternatives.

Novelty

48

Mechanism promise

33

In-category differentiation

28

Evidence quality

37

Translational signal

42

Research bench value

30

Rationale Thymogen has regulatory approval within Russia and the FSU but the evidence base is single-consortium and lacks Western replication; mechanism is conventional thymic immunobiology with no novel axis, and thymosin alpha-1 clearly dominates the therapeutic space it occupies.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic dipeptide immunomodulator

A synthetic dipeptide (Glu-Trp) developed in Russia as an immunomodulator for infectious and post-surgical immune support.

Abstract

Thymogen is the dipeptide L-glutamyl-L-tryptophan, developed in Russia at the Institute of Bioregulation and Gerontology. The compound was identified through fractionation of thymalin (bovine thymus extract) as one of the active components. Thymogen is approved in Russia and several former Soviet states for infectious diseases, post-surgical immune support, and hematopoietic recovery after chemotherapy. Mechanism includes modest T-cell maturation effects and cytokine modulation. Administered intranasally or intramuscularly. Doses are 100 micrograms per day in 3 to 10 day courses.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-129Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Thymulin

Plain-language summaryIntrigue 50 / 100

Thymulin is a 9-amino-acid zinc-dependent thymic hormone that regulates T-cell development. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

A 1970s thymic nonapeptide with legitimate immunology history but limited current research priority

Thymulin has been in the literature for over fifty years, which should tell you something. Bach and Goldstein’s groups first isolated it from thymic epithelial extracts in the 1970s, and while the zinc-dependent activation story is genuinely interesting biochemistry, the compound hasn’t really moved the needle in the decades since. Thats a long time to stay at the preclinical fringe.

Here’s the thing about the mechanism: thymulin requires bound zinc to be biologically active, and the apopeptide alone does essentially nothing. The Zn-thymulin complex is the active form, which creates a practical wrinkle that’s underappreciated in the peptide community. That zinc-dependency makes it a defensible model for studying metallopeptide pharmacology, and we think that’s actually its most legitimate research use in 2025. But the biology of thymic epithelial signaling and T-cell differentiation is well-mapped territory. There’s nothing paradigm-altering in the mechanism here.

The differentiation problem is real and it’s the biggest drag on the score. Thymosin alpha-1, the better-known thymic peptide, has reached regulatory approval in multiple jurisdictions and carries a substantially larger clinical trial base. If your research program touches thymic immunomodulation or infection adjunct applications, thymulin is not the first compound you’d reach for. It competes in a class where thymosin alpha-1 clearly outpoints it on evidence and thymosin beta-4 fragments have more active current interest. One of several, not the obvious choice.

The evidence base earns some credit. Multi-decade preclinical work across multiple independent labs is worth something, and it puts thymulin above single-consortium peptides like Epitalon. There’s limited Phase 2 data in chronic infections and some autoimmune contexts, which is real. But limited Phase 2 data and no regulatory follow-through after fifty years is a signal. The Eastern European literature cluster pattern that plagues other thymic peptides shows up here too, and it introduces replication concerns you cant fully dismiss.

What we do find interesting is the aging-thymus angle. Thymic involution is a genuine biological problem, thymulin levels decline with age alongside thymic output, and theres a plausible rationale for studying thymulin or synthetic analogs as probes of age-related immune deterioration. Some recent work from Brazilian groups on nonapeptide analogs with modified zinc-chelating residues is actually more compelling than the parent compound. That derivative work is worth watching; the original compound less so.

Honestly, for most investigators in 2025, thymulin is background reading rather than an active target. It earns its place in a complete immunology reference library, and it’s useful context when studying thymic peptides as a class. But its not a priority bench object unless you already have a thymus-specific program and need the original compound as a reference standard.

Novelty

28

Mechanism promise

38

In-category differentiation

25

Evidence quality

40

Translational signal

30

Research bench value

45

Rationale Thymulin is a mature compound with well-established mechanism and multi-decade multi-lab preclinical work, but limited clinical translation and clear competition from thymosin alpha-1, which has actual regulatory recognition in several jurisdictions. The zinc-dependency biology and aging-thymus angle provide modest bench value but don’t overcome the compound’s age, weak differentiation, and thin human evidence.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Zinc-dependent thymic nonapeptide

A zinc-dependent endogenous thymic nonapeptide secreted by thymic epithelial cells with T-cell maturation activity.

Abstract

Thymulin (Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn; molecular weight 857) is a nonapeptide originally isolated by Bach and Goldstein groups in the 1970s. The peptide is endogenously secreted by thymic epithelial cells and requires bound zinc for biological activity. Pharmacology includes promotion of T-cell differentiation, modulation of cytokine balance, and effects on autoimmune and inflammatory processes. The compound has been studied in chronic infections, autoimmune diseases, and cancer immunotherapy adjunct applications, with limited Phase 2 evidence. Available as research peptide. Doses are typically 100 to 1000 micrograms per administration.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-128Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
ARA-290 (Cibinetide)

Plain-language summaryIntrigue 78 / 100

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the helix B portion of erythropoietin. It activates a tissue-protective receptor without raising hematocrit. Investigated for neuropathic pain. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

62/100

Cleanly dissects EPO’s tissue-protective arm from erythropoiesis; novel IRR mechanism with real Phase 2 neuropathy data

Here’s the thing about ARA-290: its core insight is genuinely elegant. Erythropoietin does two very different jobs through two very different receptor complexes, and Araim’s group figured out you can have one without the other. The erythropoietic activity runs through the classical EPO homodimer. The tissue-protective, anti-inflammatory side runs through the heteromeric innate repair receptor (IRR), assembled around the CD131 beta chain it shares with IL-3 and IL-5 receptors. Brines, Cerami, and colleagues rationally designed ARA-290’s 11-residue helix B sequence to engage the IRR selectively while leaving the homodimer untouched. That isn’t lucky fragment screening; that’s real structure-guided design, and it shows.

What we like about the evidence here is the indication specificity. Small fiber neuropathy in sarcoidosis is a genuinely underserved corner of neurology. The autonomic and sensory small fibers that SFN destroys are exactly what IRR signaling appears to defend. The Phase 2 RCT in sarcoid-associated SFN showed statistically significant reductions in neuropathic pain scores alongside improvements in autonomic measures. Thats a human signal in real patients with a real unmet need, not a hopeful extrapolation from rodent nerve ligation. The bench-to-clinic translation has, at minimum, partially happened.

The limits are worth being clear about. Araim is essentially the sole development vehicle for this compound, and the trial base is still Phase 2. The mechanism literature from Brines and Cerami is solid and these are credible people with serious EPO biology credentials going back two decades, but independent multi-lab replication of the IRR pharmacology in ARA-290-specific contexts is thin. That’s not a fatal problem; it’s a real constraint on how confident you can be in the evidence package relative to compounds with broader investigator adoption.

For bench investigators, the probe value here is non-trivial. Historically, any EPO-related biology experiment had to account for the erythropoietic confound: change EPO signaling and youre also changing red cell mass, oxygen delivery, and a cascade of secondary effects. ARA-290 removes that variable cleanly. If you’re studying neuroprotection, neuroinflammation, or IRR-mediated tissue repair, this is one of the only tools that lets you probe that biology without the hematological noise. That specificity has real utility across a broader range of research contexts than the SFN indication alone implies.

We think this is a compound worth tracking for anyone working in EPO signaling, innate repair biology, or neuroprotective peptides generally. Its not top-priority for most programs, but the mechanism is genuinely novel, the clinical backing is better than most peptides in this space ever achieve, and the IRR axis may turn out to be relevant to a much wider range of tissue-injury and neuroinflammatory contexts. The score reflects real promise constrained by early-stage single-sponsor evidence, not a knock on the biology.

Novelty

62

Mechanism promise

70

In-category differentiation

68

Evidence quality

50

Translational signal

52

Research bench value

62

Rationale ARA-290 earns its score primarily on the elegance of its receptor selectivity design and genuine Phase 2 RCT backing in sarcoidosis-associated SFN; evidence quality is constrained by single-sponsor development and no Phase 3 replication yet, which keeps the overall in the low 60s rather than pushing toward the established-active tier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

EPO-derived helix B peptide

An 11-amino-acid fragment of erythropoietin’s helix B with tissue-protective activity but without erythropoietic activity.

Abstract

ARA-290 (Cibinetide; Gln-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser; CAS 1208243-50-8) is an 11-residue peptide derived from the alpha-helix B region of erythropoietin (EPO). The peptide retains the tissue-protective and anti-inflammatory activity of EPO (mediated through the heteromeric EPO/CD131 innate repair receptor) without the erythropoietic activity (mediated through the EPO receptor homodimer). The compound was developed by Araim Pharmaceuticals for diabetic neuropathy, sarcoidosis-associated small fiber neuropathy, and other neuropathic pain indications. Phase 2 trials in sarcoidosis-associated SFN showed reductions in neuropathic pain and improvements in autonomic measures. Doses are 4 mg subcutaneously per day in clinical trials.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-126Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Davunetide (NAP)

Plain-language summaryIntrigue 65 / 100

Davunetide (NAP) is an 8-amino-acid peptide derived from activity-dependent neuroprotective protein (ADNP). It supports microtubule integrity in neurons. Phase 2/3 trials in progressive supranuclear palsy were inconclusive. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

44/100

Interesting ADNP-derived tau biology probe that failed its pivotal PSP trial but retains real bench utility

Look, the honest framing on davunetide is this: it had a serious shot, it swung, and it missed. Allon Therapeutics ran a genuine pivotal trial in progressive supranuclear palsy, a devastating tauopathy with almost no treatment options, and the 2012 primary cognitive endpoint came back negative. The development program was shuttered. That’s not a single-lab anecdote gone sideways; thats a well-resourced Phase 2/3 effort that produced a definitive answer for the PSP indication. Researchers need to hold that fact in one hand before they do anything else with this compound.

The underlying biology is a different story, and it’s genuinely worth knowing. Davunetide is an eight-amino-acid fragment of ADNP, activity-dependent neuroprotective protein, which is a zinc-finger protein with a critical SIP box motif that interacts directly with microtubule-end binding proteins. The idea is that NAP stabilizes EB1/EB3-tubulin interactions and in doing so slows the hyperphosphorylation and aggregation of tau. That’s a plausible and fairly specific mechanism. Multiple labs, not just the originating Gozes group in Tel Aviv, have reproduced effects in rodent tauopathy models, including APP-PSEN1 mice and P301L transgenic lines. The preclinical corpus is solid enough to take seriously.

What we find interesting right now is the ADNP syndrome angle. ADNP haploinsufficiency causes a syndromic intellectual disability with autistic features, and the field has produced a handful of publications over the past three years examining whether NAP peptide can rescue ADNP-syndrome mouse phenotypes. The Gozes lab has continued publishing in this direction, and there are now independent replication attempts from other groups. It’s early, the N is tiny, and we haven’t seen a structured human signal, but the translational question is at least reformulated in a way that isn’t capped by the PSP failure.

As a bench tool, davunetide has real value for anyone studying microtubule dynamics in neurons, tau biology, or ADNP-interactome questions. The intranasal delivery pharmacokinetics are unusually well-characterized for a research peptide, partly because of the clinical program. Researchers have a reasonably solid CNS exposure profile to work from. Sourcing is more accessible than it was, and the peptide is structurally simple enough that vendor quality is easier to verify by HPLC than for larger fragments.

We dont think this belongs near the top of anyone’s list unless they’re specifically working the ADNP biology or designing tauopathy assays that need a reasonably specific microtubule-protective control. For those investigators, its genuinely useful. For everyone else, the failed pivotal trial is load-bearing information and the translational arrow is, at best, pointing sideways.

Novelty

48

Mechanism promise

52

In-category differentiation

38

Evidence quality

48

Translational signal

28

Research bench value

50

Rationale Davunetide scores modestly across the board because its development program ended on a clean negative result in a well-powered Phase 2/3 PSP trial (2012), crushing its translational signal even though the preclinical mechanistic work is real and multi-lab. What keeps it from falling further is the renewed relevance of ADNP biology through ADNP syndrome research and the compound’s continued utility as a probe for microtubule dynamics and tau pathology in preclinical models.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

ADNP-derived octapeptide

An eight-amino-acid fragment of activity-dependent neuroprotective protein (ADNP) studied in tauopathies and PSP.

Abstract

Davunetide (NAP, AL-108; Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln; CAS 173308-60-2; molecular weight 824.94) is an octapeptide derived from activity-dependent neuroprotective protein (ADNP). The peptide preserves microtubule integrity and reduces tau pathology in animal models of tauopathy. Davunetide was developed by Allon Therapeutics and advanced through Phase 2/3 trials in progressive supranuclear palsy (PSP); the pivotal trial in 2012 was negative for the primary cognitive endpoint, ending the development program. The compound is administered intranasally (the primary route of delivery to CNS for the formulation used in trials). Research-grade doses are 5 to 30 mg intranasally per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-125Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
P21 (Cerebrolysin-derived peptide)

Plain-language summaryIntrigue 65 / 100

P21 is a synthetic peptide derived from ciliary neurotrophic factor (CNTF) developed for neuroprotection and neurogenesis. Used in research for memory and Alzheimer disease investigations. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

45/100

Mechanistically coherent neurogenic peptide stuck behind a single-lab evidence wall

Look, P21 has one thing going for it that cerebrolysin itself never could: it’s an actual molecule. Seven amino acids, defined sequence, definable dose. When Khalid Iqbal’s group at the New York State Institute for Basic Research pulled this peptide out of the active fraction and pinned it to a CNTF-receptor-related mechanism driving dentate gyrus neurogenesis, that was genuinely useful work. Adult hippocampal neurogenesis is a serious research target, and having a defined peptide that demonstrably stimulates it in rodent models is not nothing.

The mechanism is what we find most interesting here. CNTF receptor signaling in the context of adult neurogenesis is a real frontier. P21 appears to operate through pathways related to the CNTF receptor complex, producing dose-dependent increases in new neuron formation in the dentate gyrus and corresponding improvements in spatial learning and memory in aged and AD-model rodents. That’s a coherent story. It’s not a trivial “more BDNF” hand-wave; theres a specific receptor angle with specific behavioral readouts, and the ciliary neurotrophic factor pathway is mechanistically distinct from the BDNF/TrkB axis that most neurogenic compounds lean on.

Here’s the problem: it’s still basically one group, one lab. Iqbal’s work on P21 spans several papers and the lab has real credibility in the AD field, but external replication is thin. We haven’t seen multi-lab confirmation of the neurogenesis effect or independent validation of the CNTF-receptor mechanism at scale. The animal models are relevant — transgenic AD mice and cognitively aging rodents are the right system for these claims — but rodent-to-human translation in neurogenesis research has historically been brutal. The dentate gyrus neurogenesis story itself is contested in humans in ways it simply isn’t in rodents.

There’s also no human data. None. No phase 1, no small-N pilot, not even a case series. For a compound with this much mechanistic specificity, thats a notable gap. Pharmacokinetics in humans are essentially unknown, and we dont know whether intranasal or subcutaneous administration delivers meaningful CNS levels in a primate brain at any practical dose.

What P21 does offer is genuine bench utility as a CNTF-pathway probe for investigators working in adult neurogenesis or AD-related cognitive biology. If you’re running hippocampal slice work or transgenic rodent behavioral studies, P21 is a more tractable tool than cerebrolysin’s poorly-defined mixture. That’s real value, just narrow. We think this sits as a solid single-lab story worth watching but not worth centering a program on until someone outside the Iqbal consortium picks it up and replicates the core findings independently.

Novelty

55

Mechanism promise

58

In-category differentiation

48

Evidence quality

28

Translational signal

30

Research bench value

42

Rationale P21 earns real marks for its defined CNTF-receptor mechanism and dentate gyrus neurogenesis signal in AD rodent models, but the evidence base is almost entirely Iqbal’s group at NY State IBR with no meaningful external replication and zero human data; single-lab preclinical only holds the overall to 45.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

CNTF-derived neurogenic peptide

A short peptide derived from a cerebrolysin fraction with documented hippocampal neurogenesis activity in animal models.

Abstract

P21 is a peptide of the sequence Ala-Asp-Asn-Phe-Val-Phe-Lys derived from the active fraction of cerebrolysin (or related neurotrophic preparations) and identified by Khalid Iqbal’s group at the New York State Institute for Basic Research. The compound stimulates neurogenesis in the dentate gyrus through a CNTF-receptor-related mechanism, producing dose-dependent improvements in spatial learning and memory in rodent models of cognitive aging and Alzheimer disease pathology. The compound has not been advanced to human clinical trials. Pharmacokinetics are poorly characterized in humans. The compound is sold as a research peptide; investigational doses parallel cerebrolysin range scaled to peptide content.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-124Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
DSIP (Delta Sleep Inducing Peptide)

Plain-language summaryIntrigue 60 / 100

DSIP (delta sleep-inducing peptide) is a 9-amino-acid neuropeptide that consolidates deep slow-wave sleep. Used historically in research as a sleep aid, particularly for opioid withdrawal. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

30/100

Endogenous sleep nonapeptide with uncharacterized mechanism and five decades of modest, variable results

Look, DSIP has a great origin story. The Schoenenberger-Monnier group pulls a nonapeptide out of rabbit cerebral venous blood during slow-wave sleep in 1977, names it Delta Sleep Inducing Peptide, and you’d think the field was off to the races. Forty-seven years later we’re still arguing about what receptor it binds, what signaling it drives, and whether the sleep effect is real or an artifact of model selection. Thats not a good sign for a compound this old.

The mechanism problem is the core issue here. Most peptides that have stayed in the literature this long have at least earned a defined receptor or downstream target. DSIP hasn’t. Binding sites are unconfirmed, downstream effectors are hypothesized rather than demonstrated, and the endogenous plasma and CSF concentrations oscillate with circadian rhythm in ways that suggest a role in sleep architecture but don’t specify it. We’d normally credit a compound for having a novel, incompletely understood mechanism when the incompleteness is recent. Here it’s not recent; it’s just unresolved after decades of work, which is a different thing entirely.

The clinical record is thin and honest about its thinness. The alcohol and opioid withdrawal studies from the 1980s and 90s showed some signal, but the designs were small, controls were inconsistent, and follow-up replication never materialized in a serious way. The chronic pain work is similarly suggestive without being convincing. Even the sleep effect itself, which is literally in the name, comes out as modest and variable across independent labs. When your flagship claim can’t reliably replicate over five decades, you have to question whether the effect is real at the doses studied or real only in specific species or preparation conditions.

Where we do give DSIP some credit is as a target for investigators specifically working on endogenous neuropeptide contributions to sleep regulation and stress response. It’s one of the few characterized endogenous peptides with proposed roles across sleep, circadian gating, and HPA-axis modulation, even if none of those roles are well-defined mechanistically. If your lab is trying to map what the brain does to signal sleep onset at the peptide level, DSIP is a legitimate object of study. It’s just not a tool you’d trust as a probe for a defined pathway, because the pathway isn’t defined.

Honestly, DSIP is a compound the field has never quite given up on and never quite validated. The score reflects that honestly.

Novelty

30

Mechanism promise

22

In-category differentiation

22

Evidence quality

38

Translational signal

30

Research bench value

40

Rationale DSIP scores low primarily because its mechanism remains undefined after 47 years of study, its flagship effect is conceded to be modest and variable even by its proponents, and it has been outcompeted in every clinical indication it touched. The bench value credit is real but limited: as a probe for endogenous sleep-regulatory neuropeptide signaling it’s interesting in principle, but you can’t use an uncharacterized binding site as a reliable experimental handle.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Nonapeptide neuropeptide

An endogenous nonapeptide isolated from rabbit cerebral venous blood with sleep-promoting and stress-modulating activity.

Abstract

DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu; CAS 62568-57-4; molecular weight 848.81) is a nonapeptide isolated in 1977 by the Schoenenberger-Monnier group from rabbit cerebral venous blood collected during electrically induced slow-wave sleep. The compound is endogenously present in mammalian brain and plasma, with proposed roles in sleep regulation, stress response, and circadian rhythm modulation. Despite the name, the sleep-promoting effect is modest and variable across studies. Mechanism is incompletely characterized; binding sites and downstream signaling have not been definitively established. The compound has been studied in alcohol withdrawal, opioid withdrawal, and chronic pain. Administered subcutaneously or intranasally; oral bioavailability is poor. Research-grade doses are typically 100 to 500 micrograms per administration.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-123Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Methylene Blue

Plain-language summaryIntrigue 75 / 100

Methylene blue is a phenothiazine dye used historically for malaria, methemoglobinemia, and septic shock. At low doses it serves as an alternative electron donor in mitochondria, supporting energy production when normal pathways are impaired. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

53/100

Old phenothiazine with a genuine low-dose mitochondrial story; speculative cognitive signal but solid bench utility

Look, methylene blue is a weird one. It’s the oldest synthetic pharmaceutical compound still in active use, first synthesized in 1876, and its continued relevance is more interesting than its history suggests. The thing that matters for modern research isn’t the methemoglobinemia indication or the old antimalarial work. It’s the low-dose electron-cycling story, and thats worth taking seriously.

Here’s the mechanism as best we understand it: at low doses, methylene blue acts as an electron donor to Complex III of the mitochondrial electron transport chain, bypassing dysfunctional Complex I and Complex II. For conditions where mitochondrial dysfunction is upstream of neurodegeneration, that’s a genuinely useful probe mechanism, not a hand-wavy “supports mitochondria” claim. The Gonzalez-Lima group at UT Austin has published the most credible low-dose cognitive work, documenting improvements in rodent models of TBI, aging, fear extinction, and memory consolidation. The compound also appears to inhibit tau aggregation through a separate pathway, which is what pulled it into the Alzheimer’s space as a therapeutic candidate and gave it a second mechanistic identity worth tracking independently.

Dose-dependence here is important and a bit tricky to work around experimentally. High doses produce MAO inhibition and real serotonin syndrome risk, which complicates stack protocols and confounds signal if youre not careful about where you sit on the curve. Low-dose experiments need to be precisely calibrated. The blue staining effect on tissues and excreta is cosmetically obvious and can unmask participant blinding in clinical trials, a methodological headache that’s shown up more than once in the published discussion sections.

On the clinical side: the TauRx program used leucomethylthioninium, a reduced form, in phase 2 and phase 3 Alzheimer’s trials. Phase 2 signal was real and drew serious attention. Phase 3 confirmation was inconsistent. That outcome puts methylene blue in a familiar position: multi-lab preclinical is solid, small-N human cognitive signal exists but is modest, and replication is still genuinely in progress across several independent groups.

What we actually like here is the bench utility. Methylene blue is cheap, readily sourced at pharmaceutical grade, and provides a clean pharmacological tool for probing mitochondrial redox biology. If you’re building experiments around mitochondrial dysfunction in neurodegeneration, this belongs in the toolkit. We don’t think it’s a frontier compound, and we don’t think the cognitive signal is anywhere near settled. But it earns its place as a niche probe with a real mechanistic story and a well-characterized profile that makes it genuinely useful as a research instrument.

Novelty

40

Mechanism promise

65

In-category differentiation

55

Evidence quality

50

Translational signal

45

Research bench value

65

Rationale Ancient compound elevated by a mechanistically credible low-dose electron-donor story; preclinical is multi-lab and solid but the human cognitive signal remains modest and contested, placing it firmly in niche-probe territory rather than the novel-frontier tier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Phenothiazine dye / electron donor

A phenothiazine dye used historically as an antimalarial and methemoglobinemia treatment, with mitochondrial electron-cycling activity at low doses for cognitive applications.

Abstract

Methylene blue (methylthioninium chloride; CAS 61-73-4; molecular formula C16H18ClN3S; molecular weight 319.85) is a phenothiazine dye with the longest pharmaceutical history of any synthetic compound (first synthesized 1876). The compound is FDA-approved for methemoglobinemia (high-dose, 1-2 mg/kg IV) and has historical use as an antimalarial. Low-dose methylene blue (0.5 to 4 mg/kg orally) has been studied for cognitive enhancement, traumatic brain injury, and Alzheimer disease, based on the compound’s mitochondrial electron-cycling activity (donates electrons to Complex III, bypassing dysfunctional Complex I/II). Pharmacology is complex and dose-dependent; high doses produce MAO inhibition and serotonin syndrome risk. Low-dose cognitive applications use 5 to 20 mg orally. The compound stains tissues and excreta blue, which is cosmetically obvious but harmless.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-122Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 39 40 41 42 43 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.